Our Pricing

How Weight Loss With Saxenda Works: Clinical Evidence and UK Availability

Weight loss with Saxenda has become one of the most sought-after treatment options for adults struggling with obesity or weight-related health conditions in the UK. Saxenda (liraglutide 6mg/ml) is a once-daily injectable prescription medicine that works by mimicking the natural hormone GLP-1, helping to regulate appetite and reduce calorie intake. At Cured Pharmacy, we provide genuine Saxenda from £124.99 supported by a free online consultation with UK-registered prescribers and discreet next-day delivery.

Understanding Weight Loss With Saxenda: How Liraglutide Works

Weight loss with Saxenda is achieved through its active ingredient liraglutide, a GLP-1 receptor agonist that was originally developed for type 2 diabetes management before being licensed for weight management at a higher dose [1]. Saxenda works by acting on areas of the brain that regulate appetite, leading to reduced hunger and increased feelings of fullness after eating. This mechanism helps patients consume fewer calories without the constant struggle against cravings.

Clinical trials have demonstrated that weight loss with Saxenda can be significant when combined with a reduced-calorie diet and increased physical activity [2]. In the landmark SCALE trial programme, adults using Saxenda lost an average of 8% of their initial body weight over 56 weeks, compared to 2.6% in the placebo group. Approximately 63% of patients achieved at least 5% weight loss, and 33% achieved at least 10% weight loss, results that can meaningfully improve cardiovascular risk factors and quality of life.

The injection is self-administered once daily using a pre-filled pen, with dosing gradually increased over five weeks from 0.6mg to the maintenance dose of 3mg. This titration schedule helps minimise gastrointestinal side effects that are common when starting GLP-1 therapies. Patients typically begin noticing appetite suppression within the first few weeks, though maximum weight loss effects build progressively over several months of consistent use.

Who Is Eligible for Weight Loss With Saxenda in the UK?

Saxenda is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidaemia [3]. A UK-registered prescriber must assess your suitability through a clinical consultation, reviewing your medical history, current medications, and weight loss goals. At Cured Pharmacy, this assessment is completed online in under three minutes, with prescriptions issued the same day subject to clinical approval.

Saxenda is not suitable for everyone. It should not be used during pregnancy or breastfeeding, or by individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Patients with severe renal or hepatic impairment, inflammatory bowel disease, or diabetic gastroparesis require careful evaluation before starting treatment. Your prescriber will ensure Saxenda is both safe and appropriate for your individual circumstances.

Expected Results From Weight Loss With Saxenda: What Clinical Trials Show

Weight loss with Saxenda has been extensively studied across multiple large-scale randomised controlled trials, providing robust evidence for its efficacy [2]. The SCALE Obesity and Prediabetes trial enrolled over 3,700 participants and found that after one year, patients on Saxenda lost an average of 8.4kg compared to 2.8kg in the placebo group. Importantly, 92% of the weight loss occurred within the first six months, highlighting the importance of early adherence and lifestyle modification.

Response to weight loss with Saxenda varies between individuals, influenced by factors including baseline weight, adherence to dietary changes, physical activity levels, and genetic factors affecting GLP-1 receptor sensitivity. NICE guidance recommends continuing Saxenda only if patients achieve at least 5% weight loss after 12 weeks at the maintenance dose, as this threshold predicts sustained benefit and cost-effectiveness [3]. Patients who do not reach this milestone should discontinue treatment and explore alternative options.

Beyond the number on the scale, weight loss with Saxenda has been associated with improvements in cardiometabolic markers. Trial participants experienced reductions in waist circumference, blood pressure, and HbA1c levels in those with prediabetes or type 2 diabetes [1]. These changes contribute to reduced cardiovascular risk and can delay or prevent progression to diabetes in at-risk individuals. However, Saxenda is not a cure and weight regain is common if treatment is stopped without ongoing lifestyle support.

Managing Side Effects During Weight Loss With Saxenda

The most common side effects during weight loss with Saxenda are gastrointestinal in nature, including nausea, diarrhoea, constipation, vomiting, and abdominal pain [4]. These symptoms are typically mild to moderate and tend to decrease over time as the body adapts to the medication. Starting at a low dose and gradually increasing over five weeks helps minimise these effects, and eating smaller, more frequent meals can further reduce discomfort.

Nausea affects approximately 40% of patients starting Saxenda but usually resolves within the first few weeks [4]. If nausea persists or becomes severe, patients should contact their prescriber, as dose adjustment or temporary reduction may be necessary. Staying well-hydrated and avoiding high-fat meals can also help manage gastrointestinal symptoms. In rare cases, Saxenda can cause pancreatitis; patients should seek immediate medical attention if they experience severe, persistent abdominal pain.

Other side effects of weight loss with Saxenda may include headache, dizziness, fatigue, and injection site reactions such as redness or itching. Hypoglycaemia is uncommon in patients without diabetes but can occur in those taking Saxenda alongside insulin or sulfonylureas, requiring dose adjustments of these medications. Gallbladder problems, including gallstones, have been reported in association with rapid weight loss. Regular monitoring by your healthcare provider ensures any adverse effects are identified and managed promptly.

How to Minimise Nausea and Gastrointestinal Symptoms

To reduce nausea during weight loss with Saxenda, inject at the same time each day, preferably before your largest meal or at bedtime. Avoid lying down immediately after eating, and opt for bland, low-fat foods during the initial titration phase. Ginger tea, small sips of cold water, and eating slowly can also help settle the stomach. If symptoms are severe, your prescriber may recommend pausing the dose escalation for an additional week before increasing further.

Pricing and Accessing Weight Loss With Saxenda at Cured Pharmacy

Weight loss with Saxenda is available at Cured Pharmacy from £124.99 representing the cheapest UK price for this prescription treatment. Each Saxenda pen contains 18mg of liraglutide and provides up to 30 days of treatment at the maintenance dose of 3mg daily. Our transparent pricing is displayed upfront before you begin the online consultation, with no hidden fees or subscription traps. New customers can Save £20 off their first order using code Weightlossnew at checkout.

All Saxenda purchases require completion of a free online consultation with a UK-registered prescriber, in accordance with MHRA regulations and GPhC standards. The assessment takes under three minutes and covers your medical history, current medications, weight loss goals, and suitability for GLP-1 therapy. If approved, your prescription is issued the same day and dispensed by our UK-registered pharmacy team led by superintendent pharmacist Tarun Kumar (GPhC 2233073). Orders are shipped in 100% discreet packaging with next-day delivery available.

Cured Pharmacy guarantees the lowest prices in the UK for genuine, licensed Saxenda sourced directly from authorised wholesalers. We do not stock counterfeit or grey-market products, ensuring every pen meets UK regulatory standards for safety and efficacy. Our clinical team is available by phone on (+44) 116 4646009 to answer any questions about weight loss with Saxenda, dosing, side effects, or the consultation process. We are committed to making evidence-based weight management accessible and affordable across the UK.

Combining Lifestyle Changes With Weight Loss With Saxenda

Weight loss with Saxenda is most effective when used as part of a comprehensive weight management programme that includes dietary modification and increased physical activity [2]. Saxenda is not a standalone solution; it works by reducing appetite and helping patients adhere to a reduced-calorie diet. NICE recommends a deficit of 500-600 kcal per day, which typically translates to a total intake of 1,200-1,500 kcal for women and 1,500-1,800 kcal for men, depending on baseline energy expenditure.

A balanced diet rich in vegetables, lean proteins, whole grains, and healthy fats supports sustainable weight loss with Saxenda and helps maintain muscle mass during calorie restriction. Avoiding ultra-processed foods, sugary drinks, and excessive alcohol improves both weight outcomes and cardiometabolic health markers. Many patients find that Saxenda's appetite-suppressing effects make it easier to follow these dietary guidelines without feeling deprived or constantly hungry.

Physical activity is equally important for maximising weight loss with Saxenda and preventing weight regain. The NHS recommends at least 150 minutes of moderate-intensity aerobic activity per week, such as brisk walking, cycling, or swimming, along with strength training exercises twice weekly [3]. Exercise not only increases calorie expenditure but also improves insulin sensitivity, cardiovascular fitness, and mental wellbeing. Patients who combine Saxenda with regular exercise and dietary changes achieve the best long-term outcomes.

Long-Term Weight Maintenance After Saxenda Treatment

Sustaining weight loss with Saxenda after discontinuation requires ongoing commitment to the lifestyle changes established during treatment. Clinical trials show that most patients regain some weight after stopping Saxenda, highlighting the chronic nature of obesity and the need for long-term management strategies [2]. Some patients choose to continue Saxenda for extended periods under medical supervision, while others transition to maintenance programmes involving dietary counselling, behavioural therapy, and regular physical activity.

Working with a dietitian, weight management service, or behavioural therapist can provide the support needed to maintain weight loss after Saxenda. Setting realistic goals, monitoring weight regularly, and addressing emotional or environmental triggers for overeating are key components of successful maintenance. Your prescriber can discuss the most appropriate long-term plan based on your individual response to treatment and weight loss goals.

Comparing Weight Loss With Saxenda to Other GLP-1 Therapies

Weight loss with Saxenda is one of several GLP-1 receptor agonist options available in the UK, each with distinct characteristics and efficacy profiles. Wegovy (semaglutide 2.4mg) is a once-weekly injection that has demonstrated greater average weight loss than Saxenda in head-to-head trials, with patients losing approximately 15% of body weight over 68 weeks [5]. However, Saxenda's daily dosing schedule offers more flexibility for patients who prefer frequent, smaller doses or experience side effects with longer-acting formulations.

Mounjaro (tirzepatide) is a dual GLP-1/GIP receptor agonist that has shown even greater weight loss efficacy than semaglutide, with average reductions of 20-22% in clinical trials [6]. While Mounjaro is currently licensed for type 2 diabetes in the UK, it is widely used off-label for weight management and may receive a dedicated obesity indication in the near future. The choice between Saxenda, Wegovy, and Mounjaro depends on individual factors including tolerance, cost, dosing preference, and prescriber recommendation.

For patients seeking weight loss with Saxenda, it is important to understand that all GLP-1 therapies work through similar mechanisms and share common side effects, particularly gastrointestinal symptoms. Switching between agents is possible under medical supervision if initial treatment is poorly tolerated or ineffective. At Cured Pharmacy, our clinical team can guide you through the options and help identify the most suitable GLP-1 therapy for your weight loss journey, ensuring you receive personalised, evidence-based care.

Scientific References

1. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., ... & Wilding, J. P. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22.
2. Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V., Hale, P. M., & Aronne, L. (2013). Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. International Journal of Obesity, 37(11), 1443-1451.
3. National Institute for Health and Care Excellence. (2020). Obesity: identification, assessment and management (CG189). NICE.
4. Saxenda (liraglutide) Summary of Product Characteristics. (2023). Electronic Medicines Compendium. Novo Nordisk Limited.
5. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.
6. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Garvey, W. T. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.